Kevin C. Clayton

Kevin C. Clayton

Washington, D.C.

Email [email protected]​

Phone +1 202 637 5489

Fax +1 202 637 5910

Practice groupCorporate & Finance

Kevin Clayton is responsive, gives thoughtful advice, is very knowledgeable and has a good sense of the market.

Legal 500

Kevin Clayton is a practical and experienced adviser who brings a collaborative and cost-effective approach to corporate and commercial matters. He regularly advises clients on mergers and acquisitions, equity and debt financings, joint ventures and complex contracting and corporate governance matters, particularly focusing on representation of funds, corporate investors, and emerging companies from start-up through unicorn in financing, commercial, and acquisition transactions.

In addition to his two decades of advising on mergers and acquisitions and financing transactions, Kevin also has years of experience managing a wide array of commercial matters and complex contracting arrangements, such as joint venture, license, supply, distribution, collaboration, manufacturing, service, employment, and consulting agreements.

While Kevin often represents emerging and growth-stage companies on formation, financing, commercial, and acquisition matters, he also advises later-stage and public companies, particularly with respect to investment, acquisition, joint venture and licensing transactions.

Kevin represents clients in various industry sectors, but has particular experience with matters in the life sciences and technology sectors.

Additionally, Kevin is currently a lecturer on corporate transactions at the University of Virginia School of Law.

Education and admissions


J.D., University of Virginia School of Law, 1998

B.A., University of Virginia, 1992

Bar admissions and qualifications

District of Columbia


Representative experience

Advising Ford Motor Company on Volkswagen AG's US$2.6bn investment into Ford's autonomous vehicle platform company, Argo AI.

Represented New Enterprise Associates in multiple venture capital investments.

Represented Gilead Sciences and Kite Pharma in multiple venture investments.

Represented Daimler AG in its investment in Via Transportation, Inc.

Represented OptiNose, Inc. in its US$37m Series D financing, prior equity and debt financings, and general corporate matters.

Represented a publicly traded biotechnology company in several acquisitions and divestitures and numerous strategic venture investments.

Represented Fred Hutchinson Cancer Research Center in Juno Therapeutics, Inc.'s formation and US$176m Series A financing, US$134m Series B financing, and related matters.

Represented PhishMe, Inc. in its US$42m Series C financing, prior equity and debt financings, general corporate matters, and its transaction with Malcovery Security, LLC.

Represented RTW Investments on venture investments in Monte Rosa Therapeutics' US$95m Series C financing, Acelyrin's US$250m Series B financing and InBrace's US$102m Series D financing.

Represented Dental Care Alliance, LLC in its 2015 sale to Harvest Partners, LP.

Represented Avidea Technologies in its acquisition by Vaccitech PLC.

Represented Paladin Capital on multiple venture investments.

Represented New York University in connection with Spin Transfer Technologies, Inc.'s US$70m financing and other similar transactions.

Represented a luxury vacation club in a variety of equity financings, mortgage-backed debt financings, and acquisitions.

Represented American Institutes for Research in the sale of its Assessment Division to Cambium Learning.

Represented American Institutes for Research in its acquisition of Impaq, LLC.

Loading data